Swift Comments on Trump’s Purported Plan to Use Military Funding to Build Border Wall
April 2, 2018
The Atlantic
Partner Christopher Swift is quoted in an article in The Atlantic, “Could Trump Actually Use Military Funding for His Border Wall?” about reports that the president is considering using military funds to build a wall along the Mexican border.
Using defense funds to build a border wall would likely require congressional approval, Swift said. But the “bigger question is whether Congress really wants the president treating something that has historically been a law-enforcement enterprise as a defense enterprise, as a military enterprise,” he said.
Moreover, any attempt to have the Defense Department fund the wall but not oversee it would likely result in an “administrative nightmare,” he added.
Using defense funds to build a border wall would likely require congressional approval, Swift said. But the “bigger question is whether Congress really wants the president treating something that has historically been a law-enforcement enterprise as a defense enterprise, as a military enterprise,” he said.
Moreover, any attempt to have the Defense Department fund the wall but not oversee it would likely result in an “administrative nightmare,” he added.
People
Related News
July 21, 2025
In the News
Nicholas O'Keefe Assesses 'Golden Share' in US Steel Deal
Foley & Lardner LLP partner Nicholas O'Keefe commented on the 'golden share' arrangement included as part of the approval of Nippon Steel's acquisition of U.S. Steel in Agenda, a Financial Times publication.
July 18, 2025
In the News
Matt Caplan Featured for Arrival to Foley – 'It's an exciting time'
Foley & Lardner LLP partner Matt Caplan is highlighted across press for his recent arrival to the firm's San Francisco office.
July 18, 2025
In the News
David Rosen on FDA's CRL Release – 'It hasn't happened in the past'
Foley & Lardner LLP partner David Rosen commented on the U.S. Food and Drug Administration's decision to publish a package of complete response letters to pharmaceutical companies in the PharmaVoice article, "Why FDA’s CRL release could open the door to lawsuits against pharma."